India’s government has decided to broaden the scope for invoking compulsory licensing as part of an overhaul of the country’s patent law, according to local media reports.
India’s government will introduce a bill “in the next two weeks” to overhaul its patent system and introduce pharmaceutical product patents, a minister has told local media.
Compulsory licensing of digital content could substantially reduce enforcement and transaction costs, but may also reduce supply or demand, the Congressional Budget Office argues in a new report on digital copyright issues.
Cephalon Inc. has granted Barr Laboratories Inc. a license to create a generic version of the pain killer Actiq as part of a deal with antitrust authorities to clear the drug maker’s acquisition of Cima Labs Inc.
Australia’s conservative government and the opposition Labor Party are near an agreement that would break a stalemate over intellectual-property provisions in the country’s recently negotiated free trade agreement with the U.S., according to media reports.
The European Council has postponed formal voting on a “common position” on a controversial directive on software patents, a key part of the European Union’s efforts to overhaul the patent system across the region.
The Federal Communications Commission has approved TiVo’s system to allow subscribers to send copies of recorded shows over the internet, a technology that has met strong opposition from entertainment companies.
A U.S. government agency has rejected calls for a compulsory license for a popular HIV medicine used to boost AIDS drugs, dealing a setback for activists who had hoped to use a little-known law to override a drug maker’s patent rights.
A coalition of 17 Chinese drug makers have set up a joint-stock company to produce an erectile dysfunction drug in the wake of Pfizer’s loss of patent protection for Viagra in China, according to the Beijing Morning Post.
In what the U.S. Patent and Trademark Office hails as a “major milestone,” the agency has launched a system to allow users to track the status of a public patent application online as it moves from publication to final disposition.
President George W. Bush has announced his intention to appoint Jonathan Dudas under secretary of commerce for intellectual property and director of the U.S. Patent and Trademark Office during the Congressional recess.
India will introduce a new data protection scheme “within the next few months” in an effort to bolster confidence in the country’s call centers and outsourcing industry, government official said at a New Delhi seminar last week.
The U.K. has unveiled plans for a government-backed insurance scheme that would help inventors litigate against rivals that infringe their patents, with a provision for a panel of U.S. litigators working on a contingency basis.
Anne H. Chasser, the U.S. Commissioner for Trademarks who oversaw extensive layoffs in her department during the economic downturn, will step down on Sept. 1, 2004, her office said.
The mere filing of an Abbreviated New Drug Application (ANDA) cannot constitute an act of willful infringement compensable by attorney’s fees under the Hatch-Waxman Act, the U.S. Court of Appeals for the Federal Circuit has ruled.
A number of Chinese drug makers are preparing to use the government’s rejection of a patent for Pfizer’s Viagra as a precedent for a challenge to GlaxoSmithKline’s diabetes drug Avandia, the Financial Times reports.
The Federal Circuit’s decision to rehear Phillips’ lawsuit against AWH Corp. en banc could lead to a full reexamination of many of its precedents on the interpretation of patent claims, patent attorneys say.
In a decision with broad implications, a federal judge has ruled that an internet service provider may be required to divulge the identities of subscribers sued over copyright infringement.
In a move designed to offset a broadside of litigation when India adopts product patents in 2005, India’s generics industry has offered to pay 4% of their turnover as royalty to drugs’ originators.
Microsoft Corp. has decided to appeal a warning by Japan's Fair Trade Commission over patent-related contract provisions that the FTC says violates the Antimonopoly Law.